Intervention

raltegravir

ClinicalTrials.gov intervention label

Clinical trials26

Recruiting0

Common conditions17

Lead sponsors shown15

Clinical trials

26 shown

A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, TexasNCT02302950 · 2014-09-01

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).NCT01978782 · 2014-01-01

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.NCT01779687 · 2013-03-01

RAltegravir Switch STudy: Effects on Endothelial RecoveryNCT01453933 · 2012-01-01

Effects of Intensive cART During Acute/Early HIV InfectionNCT01154673 · 2011-11-01

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirNCT01288417 · 2011-08-01

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV MedsNCT01285050 · 2011-01-01

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyNCT01227824 · 2010-10-19

Safety Study of Raltegravir in HIV/HCV Co-infected PatientsNCT01225705 · 2010-10-01

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese PatientsNCT01201239 · 2010-09-01

Pharmacokinetics of Low Dose RaltegravirNCT01159132 · 2010-04-01

Bone and Body Comp: A Sub Study of the SECOND-LINE StudyNCT01513122 · 2010-02-01

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenNCT00931463 · 2009-09-01

Effect of Antacids on the Pharmacokinetics of RaltegravirNCT00944307 · 2009-07-01

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisNCT00822315 · 2009-07-01

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard TherapyNCT00887653 · 2009-05-01

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductNCT00773708 · 2009-03-01

Effect of Raltegravir on Endothelial Function in HIV-Infected PatientsNCT00843713 · 2009-01-01

Raltegravir Therapy for Women With HIV and Fat AccumulationNCT00656175 · 2008-09-01

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the GutNCT00884793 · 2008-09-01

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 PatientsNCT00672932 · 2008-04-01

BRAVO: Background Regimen of Raltegravir on Virologic OutcomeNCT00751530 · 2008-03-01

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir TherapyNCT00661960 · 2008-03-01

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected SubjectsNCT00529243 · 2007-09-01

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After PregnancyNCT00042289 · 2003-06-09

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)NCT00377065

APPROVED_FOR_MARKETING

Common conditions

HIV Infections16 HIV6 HIV Infection4 Hepatitis C2 Acute HIV Infection1 AIDS1 Cardiovascular Disease1 Depression1 Endothelial Dysfunction1 HCV Infections1 Hypercholesterolaemia1 Hyperlipidemia1 Hypertriglyceridemia1 Infection, Human Immunodeficiency Virus I1 Inflammation1 Lipodystrophy1 Tuberculosis1

Leading sponsors

Radboud University Medical Center3 University of California, San Francisco3 Kirby Institute2 ANRS, Emerging Infectious Diseases1 Community Research Initiative of New England1 Germans Trias i Pujol Hospital1 Johns Hopkins University1 Kaiser Permanente1 Merck Sharp & Dohme LLC1 National Institute of Allergy and Infectious Diseases (NIAID)1 Shanghai Public Health Clinical Center1 The HIV Netherlands Australia Thailand Research Collaboration1 The Miriam Hospital1 The University of Texas Health Science Center, Houston1 UMC Utrecht1

Trial status mix

COMPLETED21

UNKNOWN3

APPROVED_FOR_MARKETING1

WITHDRAWN1

Phase mix

PHASE48

PHASE14

PHASE24

PHASE34

NA3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.